These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 7132061)
1. Absorption and disposition of furosemide in congestive heart failure. Brater DC; Seiwell R; Anderson S; Burdette A; Dehmer GJ; Chennavasin P Kidney Int; 1982 Aug; 22(2):171-6. PubMed ID: 7132061 [TBL] [Abstract][Full Text] [Related]
2. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function. De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of furosemide in patients with congestive heart failure. Greither A; Goldman S; Edelen JS; Benet LZ; Cohn K Pharmacology; 1979; 19(3):121-31. PubMed ID: 523503 [TBL] [Abstract][Full Text] [Related]
4. Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure. Chaturvedi PR; O'Donnell JP; Nicholas JM; Shoenthal DR; Waters DH; Gwilt PR Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):123-8. PubMed ID: 3557737 [TBL] [Abstract][Full Text] [Related]
5. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Paterna S; Di Pasquale P; Parrinello G; Amato P; Cardinale A; Follone G; Giubilato A; Licata G Eur J Heart Fail; 2000 Sep; 2(3):305-13. PubMed ID: 10938493 [TBL] [Abstract][Full Text] [Related]
6. Bumetanide and furosemide in heart failure. Brater DC; Day B; Burdette A; Anderson S Kidney Int; 1984 Aug; 26(2):183-9. PubMed ID: 6503136 [TBL] [Abstract][Full Text] [Related]
7. Furosemide kinetics in renal failure. Tilstone WJ; Fine A Clin Pharmacol Ther; 1978 Jun; 23(6):644-50. PubMed ID: 648078 [TBL] [Abstract][Full Text] [Related]
8. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259 [TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics. Sica DA Congest Heart Fail; 2003; 9(5):287-92. PubMed ID: 14564148 [TBL] [Abstract][Full Text] [Related]
11. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669 [TBL] [Abstract][Full Text] [Related]
12. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure. Rademaker MT; Charles CJ; Nicholls MG; Richards AM Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977 [TBL] [Abstract][Full Text] [Related]
14. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Cotter G; Weissgarten J; Metzkor E; Moshkovitz Y; Litinski I; Tavori U; Perry C; Zaidenstein R; Golik A Clin Pharmacol Ther; 1997 Aug; 62(2):187-93. PubMed ID: 9284855 [TBL] [Abstract][Full Text] [Related]
15. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782 [TBL] [Abstract][Full Text] [Related]
16. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291 [TBL] [Abstract][Full Text] [Related]
17. Disposition and response to bumetanide and furosemide. Brater DC Am J Cardiol; 1986 Jan; 57(2):20A-25A. PubMed ID: 3511654 [TBL] [Abstract][Full Text] [Related]
18. Variable furosemide absorption and poor predictability of response in elderly patients. Murray MD; Haag KM; Black PK; Hall SD; Brater DC Pharmacotherapy; 1997; 17(1):98-106. PubMed ID: 9017769 [TBL] [Abstract][Full Text] [Related]
19. Diuretic effect and disposition of furosemide in cystic fibrosis. Prandota J; Smith IJ; Hilman BC; Wilson JT Eur J Clin Pharmacol; 1991; 40(4):333-41. PubMed ID: 2050167 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of furosemide in advanced renal failure. Huang CM; Atkinson AJ; Levin M; Levin NW; Quintanilla A Clin Pharmacol Ther; 1974 Oct; 16(4):659-66. PubMed ID: 4422027 [No Abstract] [Full Text] [Related] [Next] [New Search]